deoxycytidine and Cancer of Esophagus

deoxycytidine has been researched along with Cancer of Esophagus in 151 studies

Research

Studies (151)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (1.32)	18.2507
2000's	72 (47.68)	29.6817
2010's	74 (49.01)	24.3611
2020's	3 (1.99)	2.80

Authors

Authors	Studies
Cai, L; Chen, S; Li, J; Wang, J; Zhao, Q	1
Cheng, X; Hu, X; Jia, Z; Liang, X; Yang, J; Zhai, Y	1
Abbasnezhad, A; Abd El-Ghafar, OA; Abhilash, L; Abouzid, KAM; Achberger, AM; Ackerman, S; Akhatayeva, Z; Akin, D; Al-Kaysi, RO; Alakhdar, AA; Alame, M; Aleksic Sabo, V; Alinezhadbalalami, N; Allen, JD; Alonso, JM; Alqatani, S; Alsayed, B; Álvarez Larraondo, M; Alvarez, M; Amini, SB; An, Z; Anasir, MI; Anderson, GH; Andremont, A; Andrés, S; Angel, S; Anigboro, AA; Anini, Y; Antonides, CFJ; Arafa, K; Arafa, RK; Aryal, UK; Asbaghi, O; Assefa, MK; Atyah, M; Avwioroko, OJ; Ayora-Talavera, G; Azpilikueta, A; Azyazov, VN; Ba, YF; Bachmann, KF; Badoual, J; Bae, SJ; Baek, SH; Bahrami, B; Bai, J; Baid-Agrawal, S; Bailey, MR; Baillie, JK; Balani, N; Balcar, VJ; Banica, T; Banks, L; Barb, J; Bardeen, CJ; Barrett, HE; Bartnikowski, N; Bashir, R; Battaglia, M; Bautista-Hernández, V; Becker, B; Beekman, FJ; Benidir, M; Benjelloun, M; Bentley, RF; Bergé, J; Berger, D; Bernsen, MR; Berraondo, P; Bhattacharya, R; Bhayani, SB; Bi, W; Bi, X; Bi, YL; Bi, Z; Bian, K; Biesecker, LG; Billadeau, DD; Blaszczyk, R; Blum, JL; Boachie, R; Boelte, K; Bogers, AJJC; Boileau, I; Bonduelle, C; Bonny, O; Bonsu, JM; Boos, LA; Borges-Argáez, R; Bouchard, PA; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, E; Boyle, AJ; Branigan, D; Briones, S; Broniowska, KA; Brossas, JY; Brown, WA; Brzezinska, J; Buitron, G; Burnier, M; Bursulaya, B; Burton, PR; Bush, AA; Busuttil, RW; Cabello-Aguilar, S; Cáceres-Farfán, M; Cacheux, V; Caffrey, PJ; Cai, B; Cai, Q; Cai, S; Cai, Y; Calders, P; Cammarota, G; Campbell, DA; Cancelli, C; Cao, Q; Cao, WH; Cao, X; Capet, M; Capoluongo, E; Carey, ME; Carnero, M; Carrasco, LI; Carreno, J; Carrillo-Reyes, J; Casini, I; Cassar, M; Catalan, G; Cattamanchi, A; Cazares-Granillo, M; Celie, B; Cen, YK; Cena, H; Cerbo, RM; Ceron, E; Cetina-Montejo, L; Chaâbane-Banaoues, R; Chabanet, C; Chace-Donahue, F; Chalfun-Júnior, A; Chan-Balan, R; Chang, CS; Chen, CS; Chen, D; Chen, J; Chen, L; Chen, PN; Chen, Q; Chen, S; Chen, W; Chen, WP; Chen, X; Chen, Z; Cheng, H; Cheng, J; Cheng, Q; Cheng, T; Chi, T; Chianelli, D; Chieppa, M; Child, CJ; Cho, JH; Cho, JY; Chogtu, B; Choi, GH; Choi, J; Choi, M; Choi, NG; Cholu, CO; Chow, ES; Chowdhury, AH; Chu, PC; Chu, Q; Chu, S; Chua, H; Chung, T; Chunyan, L; Church, JS; Civardi, E; Cobiella, J; Colinge, J; Collado, CJ; Collins, TJ; Cong, LM; Conkrite, KL; Cope, SJ; Corbett, JA; Cornet, M; Cornillot, E; Corvaisier, S; Costes-Martineau, V; Courtioux, B; Coussens, M; Covino, M; Criado, A; Cui, J; Cui, Y; Cunitz, BW; Curry, AE; Cussó, L; D'Urzo, AD; D'Urzo, KA; Dabbous, S; Dahlgren, RA; Dai, H; Dai, T; Dai, W; Dalinghaus, M; Dang, S; Davalos, RV; Davidson, H; de Andrea, CE; De Angelis, M; de Blois, E; de Carvalho, PA; De Clercq, E; De Giuseppe, R; de Jong, M; De Langhe, S; De Oliveira, L; de Souza Pinto Lemgruber, R; de Souza, LB; de Swart, J; De Wandele, I; de Woestijne, PCV; Delaney, S; Delorme, M; Delvenne, P; Deng, L; Deng, Z; Denkinger, CM; der Meulen, MHV; Deraeve, C; Desco, M; DeSilva, S; Destere, A; Dhali, A; Di Ciano, P; Dias-Santagata, D; Diskin, SJ; Djè, MK; Doddipatla, S; Doerr, AJ; Dokla, EME; Domiciano, D; Domingo, N; Dong, C; Dong, J; Dong, Q; Dong, S; Dong, X; Dong, Z; Douair, I; Douglas, TA; Doyle, SM; Drain, PK; Du, K; Du, L; Du, Q; Du, S; Duan, C; Duan, H; Duan, J; Duan, S; Duan, W; Dueluzeau, R; Dukic, L; Dunmire, BL; Duvauchelle, T; Dymek, B; Dzwonek, K; Earnest, A; Eckardt, KU; El Ghadraoui, L; El Massoudi, S; Elloumi, F; Elnour, IE; Embarak, S; Ende, M; England, K; Enikeev, D; Enyedy, I; Epple, R; Erickson, GE; Eriksson, J; Erndt-Marino, J; Errachidi, F; Etxeberria, I; Evan, AP; Fairlamb, AH; Falahi, E; Fan, CC; Fan, H; Fan, M; Fan, MZ; Fan, S; Fan, Y; Fang, CS; Fang, J; Fang, X; Fang, Z; Farmany, A; Farooqi, A; Farouk, HO; Fazelipour, S; Feng, D; Feng, J; Feng, JX; Feng, YL; Ferraz, SL; Ferreira, CR; Figenshau, RS; Finn, AV; Fiseha, T; Fleischer, AS; Fogleman, AD; Fontaine, O; Ford, CR; Fouladvand, F; Four, M; Fousteri, G; Francis, JR; Fraser, JF; Frazier, RP; Fu, H; Fu, P; Fu, YJ; Fujishima, A; Fuster, V; Gabilan, JC; Gagliani, N; Gai, QY; Galán-Arriola, C; Gale, P; Galimova, GR; Galkin, A; Gallo, A; Gallo, AA; Gang, DD; Ganschow, S; Gao, C; Gao, F; Gao, GP; Gao, H; Gao, K; Gao, M; Gao, MY; Gao, P; Gao, R; Gao, S; Gao, WJ; Gao, Y; Garbacz, P; García Ruiz, L; Garcia, EM; Garofoli, F; Gasbarrini, A; Gattinoni, L; Gaudig, M; Gbureck, U; Ge, X; Genko, N; Gentile, GL; George, MW; Gerety, GF; Gestwicki, JE; Geusens, PP; Ghassemi, M; Giardina, JD; Giebultowicz, JM; Gifford, CA; Gijsen, FJH; Gilfillan, R; Gilson, E; Gingl, K; Giuliano, C; Glybochko, P; Goessler, W; Gofflot, S; Golab, J; Goldstein, A; Golebiowski, A; Gómez, L; Gómez-Carballo, J; Gonçalves, PEO; Gonzales, R; Gonzalez-Cotto, M; González-Fernández, D; Gonzalez-Lopez de Turiso, F; Goodman, JM; Govinda Raju, S; Grimm, J; Gross, AJ; Gruenheid, S; Gu, C; Gu, FF; Gu, S; Gu, Z; Guest, RL; Gui, C; Gui, J; Guillem, A; Guo, G; Guo, L; Guo, Q; Guo, S; Guo, SW; Guo, W; Guo, Y; Guo, YG; Guo, Z; Guretzky, JA; Haenggi, M; Hahn, MS; Hakkola, J; Halim, AA; Hampel, D; Han, B; Han, BH; Han, D; Han, G; Han, J; Han, LZ; Han, R; Han, S; Han, X; Han, Z; Handley, MA; Hanke, I; Hannongbua, S; Hao, P; Happ, JT; Hara, M; Haraux, F; Hare, JL; Harper, JD; Hartley, AM; Harvey, E; Hashimoto, K; Hassan, HM; Hautajärvi, H; Hayton, TW; He, C; He, H; He, HJ; He, WP; He, Y; He, Z; Hedrick, V; Heffernan, JK; Hegrová, J; Heidarimoghadam, R; Helms, K; Hengphasatporn, K; Henry, D; Herrmann, TRW; Hesson, T; Himmelbauer, MK; Hindle, A; Hoffmann, R; Hogg, N; Hong, KB; Hong, SK; Honjol, Y; Hood, C; Hsi, RS; Hsu, JL; Hu, B; Hu, BC; Hu, D; Hu, H; Hu, J; Hu, K; Hu, M; Hu, MK; Hu, T; Hu, W; Hu, Y; Hu, Z; Hua, S; Huang, H; Huang, J; Huang, L; Huang, M; Huang, P; Huang, X; Huang, Y; Huang, Z; Hukkanen, J; Hung, MC; Huo, X; Hyötyläinen, T; Ianiro, G; Ibanez, B; Imran, M; Ireland, S; Irwin, MS; Ishiguro, H; Jackowski, K; Jackson, C; Jacob, SI; Jahromy, MH; Jakob, SM; Jang, J; Javvaji, PK; Jefferson, KK; Jena, P; Ji, H; Jiang, F; Jiang, GH; Jiang, H; Jiang, J; Jiang, X; Jiang, Z; Jiao, J; Jiménez, A; Jin, X; Jincai, W; Jintao, X; Jo, K; Jofra, T; Johari, Y; Johnson, ACM; Jones, JH; Josephine Fauci, A; Juhl, AK; Jun, S; Kaiser, RI; Kajioka, J; Kajiyama, H; Kalliyil, A; Kalthur, SG; Kamalanathan, M; Kamaldinov, T; Kanaani, L; Kang, D; Kang, J; Kang, S; Känsäkoski, P; Kaplan, DL; Karwan, M; Kasibhatla, S; Kaur, A; Kawazoe, Y; Ke, C; Keyser, J; Khalique, A; Khan, IT; Kharshoum, RM; Kher, R; Kherani, J; Ki, KK; Kikkawa, F; Kikkawa, R; Kim, BT; Kim, EH; Kim, GA; Kim, GD; Kim, HB; Kim, HG; Kim, JS; Kim, MJ; Kim, SI; Kim, SJ; Kim, Y; King, K; Kinyamu-Akunda, J; Kirkkala, T; Kjaer-Sorensen, K; Kleppinger, EL; Kloner, RA; Klopfenstein, TJ; Knappe, D; Knezevic, P; Kobos, LM; Kohli, M; Kolano, L; Kolodgie, FD; Kolte, AP; Koneru, B; Kong, D; Kong, F; Kong, X; Konggidinata, MI; Köpke, M; Koski, KG; Kotsis, F; Köttgen, A; Kouakou-Kouamé, CA; Kraemer, US; Krane, V; Krehbiel, CR; Krenning, BJ; Kretzschmar, D; Ku, KB; Kubota, Y; Kulich, P; Kumar, NG; Kupiec-Weglinski, JW; Lalani, SS; Lan, X; Landfeldt, E; Langenberg, E; Lapauw, B; Larkin, J; Lassoued, MA; Laukhtina, E; Laura Martinez, J; Laveillé, A; Lavela, P; Law, AD; Lazraq, A; Le Foll, B; Lee, BK; Lee, C; Lee, CS; Lee, EJ; Lee, EY; Lee, G; Lee, HY; Lee, JH; Lee, JJ; Lee, JO; Lee, JS; Lee, R; Lei, H; Lei, P; Lellouche, F; Lennerz, JK; Leong, W; Leslie, I; Lessem, E; Levin, M; Levinger, I; Li, C; Li, CW; Li, CX; Li, CY; Li, D; Li, H; Li, HM; Li, J; Li, L; Li, LM; Li, N; Li, S; Li, W; Li, X; Li, XX; Li, Y; Li, Z; Li, ZL; Li, ZX; Lian, Q; Liang, C; Liang, GH; Liang, H; Liang, J; Liang, X; Liao, CX; Liao, R; Ličbinský, R; Lim, YS; Lima, HK; Lin, JG; Lin, L; Lin, S; Lin, WP; Lin, Z; Liso, M; Liu, BX; Liu, C; Liu, H; Liu, J; Liu, M; Liu, Q; Liu, S; Liu, SF; Liu, SL; Liu, T; Liu, W; Liu, X; Liu, XB; Liu, Y; Liu, YY; Liu, Z; Liu, ZQ; Lobo, M; Loitzenbauer, M; López, F; Lopez, G; López, GJ; Lou, Z; Lu, IC; Lu, J; Lu, M; Lu, W; Lu, X; Lu, Y; Luhovyy, BL; Luna-Abanto, J; Luo, J; Luo, K; Luo, L; Luo, M; Luo, W; Luo, X; Luo, XM; Lv, Y; Lv, YQ; Lyu, HD; Lyu, J; Ma, C; Ma, G; Ma, L; Ma, Q; Ma, X; Ma, Y; Macha, SJ; MacLean, E; Mahalapbutr, P; Maina, T; Malfait, F; Malfertheiner, MV; Malzert-Fréon, A; Mansouri, E; Mao, C; Marcellin, E; Marchiori, PER; Marcotte, DJ; Maréchal, A; Maric, N; Maris, JM; Maron, L; Marti, CN; Martínez-Milla, J; Mateo, J; Mather, K; Mathison, CJN; Matthay, MA; Maxwell, CL; Mazier, D; Mazumder, D; Mazurkiewicz, M; Mazzucchelli, TG; McAuley, DF; Mccoy, K; McVicar, DW; Mebel, AM; Mech, A; Meester, EJ; Meiselbach, H; Melero, I; Ménard, G; Meng, X; Mengya, Y; Merle, G; Meunier, B; Mfarrej, B; Mi, K; Migueliz, I; Mikuška, P; Miladi, K; Miletich, R; Millar, JE; Mills, MR; Milne, R; Minute, L; Misiak, M; Mo, F; Modi, A; Mok, F; Molina, C; Mollen, CJ; Molteni, V; Montalto, M; Montet, D; Monti, MC; Moor, MB; Moravec, P; Morsiani, C; Murillo, E; Murugan, P; Muslem, R; Myers, RK; N'guessan, FK; Nabil, H; Nadal, J; Nadeem, M; Nafady, MM; Nafie, MS; Nair, HP; Nakano, R; Nance, J; Naren, N; Neil, CJ; Nelson, J; Nery, FC; Netsch, C; Nguyen, TH; Ni, L; Ni, YX; Nie, W; Nielsen, LK; Nigam, K; Nikolayev, AA; Nishiyama, M; Niu, LL; Niu, PP; Nock, BA; Noer, PR; Noll, G; Noll, S; Norenberg, JP; Nowicka, J; Nutho, B; O'Connor, M; Obonyo, NG; Ochiai, T; Ochoa, MC; Oh, BL; Oh, S; Olczak, J; Olivares, X; Ommurugan, B; Oosthuizen, MC; Operario, D; Orešič, M; Oshima, K; Otano, I; Ou, Y; Owen, TW; Oxvig, C; Pacey, V; Pai, M; Paik, H; Paiva, R; Palmieri, EM; Palpant, N; Pan, L; Pan, Q; Panahi, S; Pang, B; Pang, ZC; Pannecouque, C; Paris, L; Park, D; Park, DJ; Park, E; Park, EC; Park, IH; Park, JH; Park, JI; Park, S; Passmore, MR; Pattaranggoon, NC; Paun, M; Pedersen, S; Pedron, J; Peng, M; Peng, X; Penzhorn, BL; Pérez-Camargo, D; Perez-Maldonado, R; Pérez-Vicente, C; Pham, TD; Pickering, L; Pickersgill, NA; Pinault, E; Pinotsis, N; Plan, M; Pocino, K; Poh, CL; Pons, EDC; Popoff, MR; Porri, D; Pourmand, A; Pratviel, G; Prudente, DO; Qi, H; Qi, N; Qian, LY; Qiao, L; Qiao, Q; Qin, QP; Qiu, N; Qiu, SW; Qu, F; Quan, M; Quigg, A; Raee, E; Raibaud, P; Ramanitrahasimbola, D; Rapoport, L; Rasby, RJ; Rasoanirina, BNV; Raspini, B; Ratner, JR; Razafindrakoto, Z; Redd, MA; Ren, H; Ren, N; Rey, J; Reynolds, CP; Rich, PR; Richards, CJ; Rigol, M; Rimoldi, S; Robert, P; Rodrigues, AE; Roe, JH; Rohde, S; Rokita, JL; Roland, J; Rombaut, L; Ronkainen, J; Rothenberg, SM; Roy, SC; Ruan, Z; Rucker, PV; Rueda, D; Ruhwald, M; Rungrotmongkol, T; Rupert, AS; Rusjan, P; Ryabov, AD; Rysä, J; Saad, NES; Sabioni, P; Sadow, PM; Sahai, N; Salem, HF; Salinas, B; Salonurmi, T; Samé Guerra, D; Sánchez, J; Sanchez-González, J; Sanmamed, MF; Sansores-Peraza, P; Santoro, JC; Santschi, PH; Saritas, T; Sarkisova, Y; Savolainen, MJ; Scherberich, JE; Schlom, DG; Schmelz, EM; Schmid, MC; Schneider, MP; Schumacher, S; Schwartz, JC; Schwartzer, JJ; Schwehr, K; Schweitzer, DH; Scott, ME; Sedky, NK; See Hoe, L; Sejian, V; Selvaraju, S; Sen, SK; Seo, G; Šerý, O; Settles, JA; Sfar, S; Shaffer, J; Shan, GL; Shang, Q; Shannahan, JH; Shao, B; Shao, H; Shao, J; Shao, ZH; Shasha, Y; Shaw, K; Sheeba, V; Shekar, K; Shen, G; Shen, H; Shen, XD; Shen, Y; Sherrell, PC; Shete, PB; Shi, AX; Shi, J; Shi, JH; Shi, S; Shi, X; Shigeta, Y; Shimbo, A; Shin, E; Sikka, N; Silhavy, TJ; Simanon, N; Simard, S; Simon, J; Simon, M; Simpson, SD; Simundic, AM; Since, M; Singh, B; Singhroy, DN; Sinisterra, OT; Smith, EH; Sobreira, TJP; Solanes, N; Somasundar, Y; Sommerer, C; Sonei, A; Song, B; Song, E; Song, J; Song, M; Song, Y; Soo Lee, M; Sorensen, MD; Sournia-Saquet, A; Spaepen, E; Spirk, D; Srivastava, S; Stancill, JS; Stanczak, PS; Starenki, D; Starr, F; Step, DL; Steubl, D; Stigliani, JL; Stráská, J; Sträter, N; Su, ZZ; Sudano, I; Suen, JY; Suh, HJ; Sui, ZY; Suico, JG; Suleiman, K; Sumon, K; Sun, HB; Sun, J; Sun, L; Sun, LL; Sun, M; Sun, Q; Sun, W; Sun, X; Sun, XF; Sun, Y; Sun, YB; Sun, YH; Sun, YN; Sun, Z; Sunada, K; Suzuki, S; Sylvan, JB; Takala, J; Talla, D; Tamir, Z; Tan, SJ; Tanda, S; Tang, H; Tang, J; Tang, LF; Tang, SJ; Tang, Y; Tao, FB; Tappel, R; Taratkin, M; Teijeira, Á; Tellew, JE; Thomas, AM; Thomas, SG; Thomson, SR; Tian, J; Tie, Y; Tirado, JL; Tolonen, A; Tosato, G; Tronnet, A; Tsai, S; Turtoi, A; Turtoi, E; Tvrdoňová, M; Tyagi, A; Tzou, DT; Uddin Ahmad, Z; Urias, E; Usawachintachit, M; Ustriyana, P; Utsumi, F; Vacca, M; Vaculovič, T; Vaidya, SS; Valentin, A; Valgepea, K; van den Berg, P; van den Bergh, JP; van der Heiden, K; van Gaalen, K; Van Gemert, W; van Haard, PMM; van Hest, JCM; Vecchiarelli, E; Večeřa, Z; Venkatesh, R; Verhaeghe, P; Verhagen, HJ; Vetter, JM; Vieira, D; Vilchez-Tschischke, JP; Villena-Gutierrez, R; Villoslada Terrones, V; Vital-Jacome, M; Voelkl, J; Vogel, K; Vogrin, S; Volke, D; von Bahr, V; Vysloužil, J; Wade, TL; Wagner-Gillespie, M; Walsh, SW; Wan, LJ; Wan, SP; Wang, AL; Wang, B; Wang, BY; Wang, C; Wang, D; Wang, F; Wang, H; Wang, HR; Wang, HY; Wang, J; Wang, JY; Wang, K; Wang, L; Wang, LF; Wang, P; Wang, Q; Wang, R; Wang, SF; Wang, SP; Wang, SR; Wang, T; Wang, W; Wang, WP; Wang, X; Wang, XJ; Wang, Y; Wang, YL; Wang, YN; Wáng, YXJ; Wang, Z; Wang, ZF; Wang, ZY; Waning, B; Warner, JM; Washington, SL; Watson, AK; Wei, B; Wei, C; Wei, F; Wei, X; Wei, Y; Wemhoff, AP; Wen, Z; Weng, TT; Wesdemiotis, C; Wheeler, DA; Wildner, M; Wilson, BK; Wirth, LJ; Wissler, M; Wu, F; Wu, G; Wu, J; Wu, KH; Wu, MC; Wu, P; Wu, PK; Wu, S; Wu, W; Wu, X; Wu, XP; Wu, Y; Wyatt, E; Wyllie, S; Xia, Y; Xiao, BH; Xiao, SZ; Xiao, W; Xiao, X; Xiao, Z; Xie, D; Xie, K; Xie, X; Xie, Y; Xie, YF; Xin, S; Xin, Z; Xing, Q; Xing, WQ; Xiong, D; Xiong, X; Xu, C; Xu, D; Xu, F; Xu, G; Xu, H; Xu, J; Xu, JY; Xu, L; Xu, N; Xu, W; Xu, X; Xu, Y; Xu, YM; Xue, H; Xue, J; Xue, Z; Yan, R; Yan, SQ; Yan, W; Yan, X; Yan, Z; Yang, C; Yang, D; Yang, F; Yang, FC; Yang, G; Yang, J; Yang, M; Yang, P; Yang, Q; Yang, R; Yang, S; Yang, SJ; Yang, TWW; Yang, X; Yang, Y; Yang, Z; Yao, C; Yao, L; Yao, LP; Yao, M; Yao, T; Yao, W; Yao, Y; Yaseen, T; Yazdani, V; Ye, J; Ye, S; Yerys, BE; Yi, HWL; Yi, JL; Yin, F; Yin, J; Yin, Y; Yin, Z; Yong, ZP; Yongli, S; Yoo, JS; Yoshikawa, N; You, Q; Yu, B; Yu, CQ; Yu, H; Yu, HG; Yu, J; Yu, L; Yu, Q; Yu, X; Yu, Y; Yu, YK; Yu, Z; Yuan, Q; Yuan, R; Yuan, W; Yuan, X; Yuan, Y; Zager, RA; Zagozdzon, A; Zaller, N; Zang, YP; Zappi, ME; Zelikoff, JT; Zeman, T; Zhai, X; Zhan, P; Zhang, B; Zhang, C; Zhang, G; Zhang, H; Zhang, HB; Zhang, J; Zhang, JS; Zhang, L; Zhang, M; Zhang, Q; Zhang, RX; Zhang, S; Zhang, T; Zhang, W; Zhang, WH; Zhang, X; Zhang, XX; Zhang, Y; Zhang, YQ; Zhang, YW; Zhang, Z; Zhang, ZH; Zhao, D; Zhao, FL; Zhao, K; Zhao, L; Zhao, M; Zhao, R; Zhao, S; Zhao, W; Zhao, WG; Zhao, X; Zhao, Y; Zheng, G; Zheng, J; Zheng, S; Zheng, W; Zheng, Y; Zheng, YG; Zhong, Z; Zhou, C; Zhou, D; Zhou, H; Zhou, HY; Zhou, L; Zhou, Q; Zhou, X; Zhou, Y; Zhou, YL; Zhou, Z; Zhu, J; Zhu, L; Zhu, N; Zhu, X; Zhu, XF; Zhu, Y; Zhu, Z	1
Honeywell, RJ; Opperman, RCM; Peters, GJ; Poel, D; van der Vliet, HJ; van Zweeden, AA; Verheul, HMW	1
Damelin, LH; Jivan, R; Mavri-Damelin, D; Mynhardt, C; Peres, J; Prince, S; Veale, RB	1
Ma, Z; Xue, X	1
Apisarnthanarax, S; Hallemeier, CL; Huguet, F; Jabbour, SK; Murphy, JD; Olsen, JR; Tait, D	1
Altomare, I; Arrowood, CC; Bendell, JC; Blobe, GC; Brady, JC; Conkling, P; Cushman, SM; Favaro, J; Hsu, SD; Hurwitz, HI; Meadows, KL; Morse, MA; Nixon, AB; Pang, H; Uronis, HE; Zafar, SY	1
Scheithauer, W; Van Cutsem, E	1
Al-Batran, SE; Bichev, D; Haller, B; Homann, N; Lordick, F; Lorenzen, S; Luley, K; Pauligk, C; Schumacher, G; Schuster, T; Thuss-Patience, P	1
Barbachano, Y; Chau, I; Coxon, F; Crosby, T; Cunningham, D; Falk, S; Ferry, D; Frances, A; Gonzalez, D; Iveson, T; Mansoor, W; Middleton, G; Okines, AF; Okines, C; Peckitt, C; Saffery, C; Slater, S; Smith, D; Waddell, T; Wadsley, J; Waters, J; Wotherspoon, A	1
Bashir, N; Blazeby, J; Bridgewater, JA; Crosby, T; Cunningham, D; Falk, S; Geh, JI; Gollins, S; Griffiths, G; Hurt, CN; Maughan, T; Mukherjee, S; Ray, R; Roy, R; Staffurth, J	1
Bowrey, DJ; Cunnell, M; Khanna, A; Madhusudan, S; Parsons, SL; Reece-Smith, AM; Thomas, A	1
Feng, FY; Guan, ZZ; Jiao, SC; Jin, YN; Li, J; Pan, LX; Qin, SK; Shen, L; Tao, M; Wang, JJ; Wang, LW; Wang, YJ; Xu, JM; Yu, SY; Zheng, LZ	1
Arnold, D; Geissler, M; Grothe, W; Hofheinz, RD; Moehler, M; Reinacher-Schick, A; Schmoll, HJ; Seufferlein, T; Stein, A; Thuss-Patience, PC	1
Popa, EC; Shah, MA	1
Li, X; Lin, S; Lin, W; Lin, Y; Wang, H	1
Bailey, IS; Byrne, JP; Curtis, NJ; Kelly, JJ; Noble, F; Underwood, TJ	1
Arena, MG; Barba, M; Belli, F; Di Lauro, L; Fattoruso, SI; Giannarelli, D; Maugeri-Saccà, M; Paoletti, G; Pizzuti, L; Sergi, D; Tomao, S; Vici, P	1
Agterof, M; Borel-Rinkes, I; Lolkema, MP; Overkleeft, E; Reerink, O; Schipper, M; Siersema, P; Ubink, I; van der Sluis, P; van Hillegersberg, R; Vleggaar, F; Voest, E; Wijrdeman, H	1
Gonda, T; Halmos, B; Melamed, J; Miller, G; Rotterdam, H; Seetharamu, N; Villanueva, G	1
Cosson, VF; Lehle, M; Lum, BL; Ng, VW	1
Bu, L; Chen, L; Dai, G; Li, J; Liu, Y; Pan, H; Piao, Y; Qin, S; Shen, L; Shu, Y; Wang, J; Wang, L; Xu, J; Xu, R; Yang, Z; Yu, S	1
Jiang, Z; Liang, Y; Liu, F; Song, X; Wang, W; Wu, P; Xing, L; Xu, D; Yu, X; Zang, Q; Zhang, J	1
Barham, CP; Blazeby, JM; Brookes, ST; Crosby, T; Donovan, JL; Falk, SJ; Griffin, SM; Hollingworth, W; Hollowood, AD; Krysztopik, R; Nicklin, J; Streets, CG; Strong, S; Titcomb, D; Wilson, C	1
Ahlgren, J; Akin, E; Bishop, C; Guebre-Xabiher, H; Kirkel, D; Patel, N; Schuck, S; Siegel, P; Siegel, R; Simmens, S	1
Achiam, M; Bæksgaard, L; Duval, L; Holländer, C; Ladekarl, M; Larsen, AC; Pfeiffer, P; Schønnemann, K; Thorlacius-Ussing, O; Yilmaz, MK	1
Brammer, K; Catton, JA; James, EJ; Parsons, SL; Randhawa, N; Tan, BH; Welch, NT	1
Calkins, SM; Cinar, P; Kelley, RK; Venook, AP	1
Bassermann, F; Becker, K; Eisenmenger, A; Haag, GM; Helbig, U; Karapanagiotou-Schenkel, I; Lordick, F; Lorenzen, S; Pohl, M; Riera Knorrenschild, J; Rüschoff, J; Schnoy, E; Stocker, G; Thuss-Patience, P; Weißinger, F	1
André, T; Bachet, JB; Chibaudel, B; Cohen, R; de Gramont, A; Hentic, O; Louvet, C; Samalin, E; Soularue, É; Tournigand, C; Zaanan, A	1
Doki, Y; Kurokawa, Y; Miyata, H; Miyazaki, Y; Mori, M; Nakajima, K; Takahashi, T; Takiguchi, S; Yamasaki, M	1
Ahn, HK; Ahn, MJ; Hwang, IG; Jung, HA; Jung, KS; Kim, HS; Kim, M; Kim, SM; Lee, J; Lee, JY; Lee, MY; Lee, SC; Lee, SI; Lim, DH; Lim, SH; Park, KW; Park, SH; Sun, JM; Yi, SY	1
Li, R; Li, Y; Liu, Y; Qiao, X; Shi, G; Tan, B; Tian, Y; Wang, J; Xu, Q; Yang, P; Zhang, J; Zhao, Q	1
Calpena, R; Gallego, J; Lacueva, FJ; Martinez-Blasco, A; Mingol, F; Morcillo, MA; Moya, P; Orduña, A; Ruiz, JA; Sola-Vera, J	1
Han, SM; Han, Y; Shi, SB; Tian, J; Wang, YS	1
Anthoney, A; Cheeseman, S; Collinson, M; Dent, J; Hall, PS; Howard, H; Jones, M; Last, K; Lord, SR; Lowe, C; Marshall, H; Roy, R; Seymour, MT; Swinson, D; Velikova, G	1
Han, X; Lu, N; Pan, Y; Xu, J	1
Kurokawa, Y; Sasako, M	1
Hang, X; Liu, C; Sun, Q; Wang, D; Zhong, B	1
Gennatas, C; Gennatas, S; Michalaki, V	1
Chau, I; Cunningham, D; Harper, P; Hawkins, R; Hickish, T; Iveson, T; Nicolson, M; Norman, AR; Oates, J; Seymour, M	1
An, GL; Gu, SZ; Li, XH; Lian, JW; Pan, BR; Qin, TJ; Tian, F; Zhao, XH	1
Clark, KR; Javle, MM; LeVea, C; Nava, HR; Nwogu, CE; O'Malley, L; Pendyala, L; Prey, JD; Schiff, MD; Smith, PF; Vinjamaram, S; Wilding, GE; Yang, G	1
Baselga, J; Benson, M; Cunningham, D; Hill, A; Kurek, R; Lüpfert, C; Oates, J; Rao, S; Starling, N; Wotherspoon, A	1
Cho, KJ; Choi, KD; Jung, HY; Kim, JH; Kim, MK; Kim, SB; Kim, YH; Lee, GH; Park, SI; Ryu, JS; Shin, JH; Song, HJ; Song, HY	1
Ahn, BM; Chae, YS; Jeon, SW; Kim, JC; Kim, JG; Lee, EB; Lee, SJ; Moon, JH; Park, IK; Sohn, SK	1
Kolluri, RB; Raouf, S; Tipples, K	1
Dinter, D; Hochhaus, A; Hofheinz, RD; Kripp, M; Lukan, N; Ströbel, P	1
Coxon, F; Cunningham, D; Daniel, F; Iveson, T; Middleton, G; Nicolson, M; Norman, AR; Oates, J; Rao, S; Starling, N	2
Allum, W; Ashley, S; Benson, M; Brown, G; Chau, I; Cunningham, D; Oates, J; Okines, A; Riddell, A; Starling, N; Stavridi, F; Thomas, J; Thompson, J; Wotherspoon, A	1
Ashley, S; Chau, I; Cunningham, D	1
Cunningham, D; Kang, YK; McCloud, P; Norman, AR; Okines, AFC	1
Balducci, M; D'Agostino, GR; Dinapoli, N; Mantini, G; Massaccesi, M; Mattiucci, GC; Meduri, B; Micciché, F; Nardone, L; Salvi, G; Valentini, V	1
Gong, HY; Huang, W; Li, BS; Li, HS; Lin, HQ; Sun, HF; Wang, LY; Wang, ZT; Wei, YM; Yi, Y; Zhang, ZC; Zhou, T	1
Saif, MW; Shi, N; Zelt, S	1
Fareed, KR; Ilyas, M; Kaye, PV; Lobo, DN; Madhusudan, S; Parsons, SL; Soomro, IN	1
Fan, QX; Huang, JY; Sun, Y; Zhang, YQ	1
Feng, FY; Fu, M; Liang, X; Lin, C; Luo, Y; Zhang, XY	1
Cummins, MM; Ganju, V; Gebski, V; Gibbs, D; Sourjina, T; Stockler, M; Strickland, A; Tebbutt, NC; Van Hazel, G; Zalcberg, J	1
Jørgensen, JT	1
Ashley, S; Cunningham, D; Okines, AF	1
Burris, HA; Clark, BL; Farley, C; Gray, JR; Greco, FA; Hainsworth, JD; Lane, CM; Meluch, AA; Spigel, DR	1
Hantel, A; Hwang, J; Javle, M; Khorana, AA; Kiefer, G; Lo, SS; Rajasenan, K; Ramanathan, RK; Schmotzer, A; Shayne, M; Simon, S; Wang, H	1
Andersen, M; Jensen, HA; Pfeiffer, P; Schønnemann, KR; Vestermark, LW; Yilmaz, M	1
Archer, C; Beadman, C; Cunningham, D; Gilligan, D; Kurek, R; Oates, J; Rao, S; Ruhstaller, T; Starling, N; Sumpter, K; Valladares-Ayerbes, M; Wilke, H	1
Aggarwal, S; Goel, G; Jauhri, M; Negi, A	1
Allali, M; Bergmann, U; Kummer, G; Riebeling, J; Schultheis, B; Sendler, A; Sendler, U; Strumberg, D; Tannapfel, A	1
Ashley, SE; Chau, I; Chua, YJ; Cunningham, D; Oates, J; Okines, AF; Saffery, C; Turner, A; Webb, J	1
Ahn, JS; Ahn, YC; Cho, EY; Im, YH; Kim, K; Kim, KH; Lee, S; Park, K; Park, YH; Shim, YM	1
Bernal, P; Byrd, J; Malik, I	1
Andersen, M; Pfeiffer, P; Schønnemann, KR; Yilmaz, M	1
Aklilu, M; Blackstock, AW; Clark, P; Geisinger, KR; Isom, S; Levine, EA; Mishra, G; Monjazeb, AM; Riedlinger, G	1
Ahn, SD; Choi, EK; Kim, JH; Kim, SB; Lee, SW; Lee, YS; Park, JW; Park, SI; Song, SY; Yoon, SM	1
Gossage, JA; Hale, PC; Mamidanna, R; Manifold, DK; Newman, G; Pantling, AZ; Robinson, A	1
Danso-Appiah, A; Eastwood, A; Norman, G; Palmer, S; Rice, S; Spackman, E; Stirk, L; Suh, D	1
Abel, U; Debus, J; Haag, GM; Haberkorn, U; Jäger, D; Lordick, F; Lorenzen, S; Münter, MW; Stange, A; von Gall, C; Weichert, W; Weitz, J	1
Abd-Ellatif, EA; El-Hadaad, HA; Wahba, HA	1
Lolkema, MP; van der Horst, S; van der Sluis, PC; van Hillegersberg, R; Verhage, RJ	1
Ashley, S; Chau, I; Cunningham, D; Gujral, DM; Hawkins, MA; Leonulli, BG; Tait, D	1
Choi, HL; Han, JY; Kim, HT; Kim, HY; Lee, JS; Nam, BH; Yun, T	1
Baglin, TP; Ford, H; Hardwick, RH; Peters, CJ; Rollins, KE; Safranek, PM	1
Cho, KJ; Choi, KD; Jung, HY; Kim, JH; Kim, SB; Kim, YH; Koo, DH; Lee, GH; Park, SI; Shin, JH; Song, HJ; Song, HY; Yoon, DH	1
Bellavia, T; Damodaran, S; Khushalani, NI; Sait, SN; Wang, ES; Wetzler, M	1
Abe, T; Baba, E; Boku, N; Hamamoto, Y; Hatake, K; Miyata, Y; Nishina, T; Ohashi, Y; Ohtsu, A; Omuro, Y; Sasaki, Y; Satoh, A; Satoh, T; Sawaki, A; Takiuchi, H; Tamura, T; Yamaguchi, K	1
Helin, H; Karhumäki, L; Kauppi, JT; Kemppainen, J; Oksala, N; Räsänen, JV; Salo, JA; Sihvo, EI	1
Feng, XZ; Han, JQ; Sheng, W	1
Cai, RG; Chen, L; Fan, QX; Hao, XZ; Huang, J; Liu, AN; Sun, Y; Wang, JW	1
Ellemann, AC; Kofoed, SC; Lundsgaard, M; Svendsen, LB	1
Arnold, D; Bichev, D; Breithaupt, K; Daum, S; Florschütz, A; Gahn, B; Glanemann, M; Hofheinz, RD; Kneba, M; Kretzschmar, A; Mantovani-Löffler, L; Reichardt, P; Schlattmann, P; Schumacher, G; Thuss-Patience, PC	1
Arasaradnam, RP; Borman, RA; Goodyear, SJ; James, S; Jarvie, EM; Nwokolo, CU; Sanger, GJ; Snead, D; Sung, EZ	1
Crosby, T; Evans, M; Griffiths, G; Gwynne, S; Hurt, C; Joseph, G; Nixon, L; Spezi, E; Staffurth, J; Wills, L	1
Gu, J; Li, YM; Wang, HX; Wang, M; Wang, YJ; Wu, MH	1
Allum, WH; Blazeby, JM; Coxon, F; Cunningham, D; Evans, L; Falk, S; Ford, D; Griffin, M; Hall, M; Iveson, TJ; Langley, RE; Middleton, GW; Okines, AF; Petty, RD; Plummer, C; Seymour, M; Slater, S; Smith, D; Stenning, SP; Stevenson, L; Thompson, LC; Waters, J	1
Adewoye, AH; Bampton, CL; Bass, MB; Bodoky, G; Eatock, MM; Nanayakkara, N; Strickland, AH; Sun, YN; Swieboda-Sadlej, A; Tebbutt, NC; Valladares-Ayerbes, M; Van Cutsem, E; Zhong, ZD	1
Becker, K; Belle, S; Ebert, MP; Hofheinz, R; Krause, A; Mayr, M; Röcken, C; Schmid, RM; Schulte, N	1
Bubis, JA; Dragnev, KH; Gordon, SR; Gui, J; Lisovsky, M; Rigas, JR; Sutton, JE; Wood, MD; Zaki, BI	1
Blackie, R; Evans, TR; Fullarton, GM; McDonald, AC; McInnes, A; Morrison, R; Paul, J; Pentheroudakis, G; Raby, N; Soukop, M	1
Arnold, D; Hoepffner, N; Kern, M; Neuhaus, P; Oettle, H; Riess, H; Settmacher, U	1
Bares, R; Bartusek, G; Dittmann, H; Dohmen, BM; Kehlbach, R; Pritzkow, M; Sarbia, M	1
Hehlmann, R; Hochhaus, A; Hofheinz, RD; Weisser, A; Willer, A	1
Rich, TA; Shepard, R	1
Giglio, P; Groves, MD; Tremont-Lukats, IW	1
Abbruzzese, JL; Benedetti, JK; Chansky, K; Macdonald, JS; Pluenneke, RE; Urba, SG; VanVeldhuizen, PJ	1
Giaccone, G; Kroep, JR; Peters, GJ; Pinedo, HM; Van Bochove, A; Van Groeningen, CJ	1
Bagajevas, A; Cesas, A	1
Codacci-Pisanelli, G; Kroep, JR; Loves, W; Peters, GJ; Sigmond, J	1
Haller, DG	1
Chong, G; Cunningham, D	1
Cunningham, D; Harper-Wynne, C; Hickish, T; Hill, M; Iveson, T; Nicolson, M; Norman, AR; Oates, J; Rao, S; Sumpter, K; Tebbutt, N; Ward, C	1
Bredenkamp, R; Duyster, J; Hennig, M; Lersch, C; Lordick, F; Lorenzen, S; Peschel, C; von Delius, S	1
Bubis, JA; Dragnev, KH; Rigas, JR	1
Akerman, P; Barnett, JM; Berkenblit, A; Harrington, D; Iannitti, D; Maia, C; Miner, T; Nadeem, A; Rathore, R; Roye, D; Safran, H; Stuart, K; Tsai, JY	1
Ahuja, H; Bailey, H; Berlin, JD; Hansen, R; Jumonville, A; Kim, K; McFarland, T; Morgan-Meadows, S; Mulkerin, D; Saphner, T; Thomas, JP	1
Cameron, D; Dunlop, D; Eatock, M; McClory, B; Millar, J; Morrison, A; Philips, H; Price, A; Scullin, P; Wall, L	1
Alberts, SR; Fitch, TR; Foster, NR; Jatoi, A; Knost, JA; Murphy, BR; Nikcevich, DA; Rowland, KM	1
Alberts, SR; Dakhil, SR; Flynn, PJ; Foster, N; Giordano, KF; Jatoi, A; Mailliard, JA; Nikcevich, DA; Stella, PJ; Tschetter, LK	1
Ando, K; Kamata, T; Kitabayashi, H; Ochiai, T; Shimada, H; Tsujii, H; Yamada, S; Yasuda, S	1
Abbruzzese, JL; Atkins, JN; Blanke, CD; Dakhil, SR; Gandara, DR; McCoy, SA; Paradelo, JC; Williamson, SK; Yost, KJ	1
Anthoney, DA; Burge, ME; Halstead, F; Jackson, DP; Seymour, MT; Smith, D; Topham, C	1
Boot, H; Corporaal, S; Legdeur, MC; Russel, MG; Smit, WM; van der Palen, J	1
Ajani, J	1
Hengge, UR; Marini, A	1
Ahmad, SA; Firdaus, I; Howington, JA; James, L; Jazieh, AR; Lowy, AM; Redmond, K; Reed, MF; Rose, P; Roychowdhury, D; Safa, M; Sussman, JJ	1
Bendell, JC; Blobe, GC; Czito, BG; D'Amico, TA; Fernando, NH; Harpole, DH; Honeycutt, W; Hurwitz, HI; Kelsey, CR; Morse, MA; Willett, CG; Yu, D	1
Dhillon, S; Scott, LJ	1
Kang, YK	1
Holcombe, RF; Ou, SH	1
Bremer, M; Karstens, JH; Schwarte, S; Wagner, K	1
Doorn, L; Eskens, FA; van der Gaast, A; van Gameren, EC; van Meerten, E	1
Albertsson, M; Carstens, H	1
Akerman, P; Evans, D; Jean, M; Kennedy, T; Millis, R; Miner, T; Safran, H	1
Cho, EY; Hong, YS; Im, YH; Kang, WK; Kim, HS; Kim, K; Kim, MJ; Lee, HR; Lee, J; Park, K; Shim, YM	1
Filip, DJ; Grossniklaus, HE; Lee, WB; Sy, HM	1
André, T; Blanchard, P; Huguet, F	1
Akerman, P; Berkenblit, A; Chauhan, B; Cruff, D; Evans, D; Habr, F; Harrington, D; Iannitti, D; Kennedy, T; Maia-Acuna, C; Miner, T; Safran, H; Sears, D; Stuart, K	1
Bendell, JC; Chino, JP; Clough, RW; Czito, BG; D'Amico, TA; Hurwitz, HI; Kelsey, CR; Morse, MA; Willett, CG	1
Ajani, JA; Cen, P	1
Albertsson, M; Friesland, S; Frykholm, G; Johansson, B; Kadar, L; Letocha, H; Wagenius, G	1
Cho, KJ; Choi, KD; Jung, HY; Kim, JH; Kim, SB; Kim, YH; Lee, GH; Lee, SS; Park, SI; Ryu, JS; Shin, JH; Song, HY	1
Borghesi, S; Hawkins, MA; Tait, D	1
Chan, HK; Chan, KC; Chan, PL; Ko, JM; Kwong, FM; Law, S; Liu, ET; Lo, PH; Lung, ML; Miller, LD; Srivastava, G; Stanbridge, EJ; Tang, JC; Tsao, SW; Yang, LC; Yau, WL; Yu, ZY	1
Dees, EC; Goldberg, RM; Hayes, DN; Lee, CB; Moore, DT; Socinski, MA; Stinchcombe, TE	1
Bölke, E; Budach, W; Peiper, M	1
Ariyoshi, Y; Fukuoka, M; Fukuyama, E; Furue, H; Furuse, K; Gemma, A; Harada, M; Hasegawa, K; Horikoshi, N; Kanamaru, R; Kudoh, S; Kurihara, M; Kurita, Y; Mori, K; Niitani, H; Ota, K; Taguchi, T; Tsukagoshi, S; Wakui, A; Yoneda, S	1
Catik, A; Kroep, JR; Peters, GJ; Pinedo, HM; van Groeningen, CJ; van Moorsel, CJ; Vermorken, JB	1
Bhupalam, L; Fleming, DR; Glisson, SD; Goldsmith, GH; LaRocca, RV; Michelson, GD	1
Einhorn, LH; Kindler, HL; Kraut, M; Masters, G; Mitchell, E; Nicol, S; Raghavan, D; Sandler, AB	1
Genvresse, I; Harder, H; Lange, C; Possinger, K; Schanz, J; Schweigert, M; Späth-Schwalbe, E	1
Ben-Josef, E; Du, W; Levin, KJ; Philip, PA; Shields, AF; Vaishampayan, UN; Vaitkevicius, VK	1

Reviews

18 review(s) available for deoxycytidine and Cancer of Esophagus

Article	Year
Considering gemcitabine-based combination chemotherapy as a potential treatment for advanced oesophageal cancer: A meta-analysis of randomised trials. International journal of clinical practice, 2020, Volume: 74, Issue:7 Topics: Administration, Intravesical; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Drug Administration Schedule; Esophageal Neoplasms; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic	2020
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus	2016
The role of oxaliplatin in the management of upper gastrointestinal tract malignancies. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2003, Volume: 5 Suppl 3 Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Esophageal Neoplasms; Fluorouracil; Gemcitabine; Humans; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Stomach Neoplasms; Survival Rate	2003
Capecitabine in the treatment of esophageal and gastric cancers. Expert opinion on investigational drugs, 2013, Volume: 22, Issue:12 Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Capecitabine; Chemoradiotherapy; Deoxycytidine; Esophageal Neoplasms; Fluorouracil; Humans; Stomach Neoplasms	2013
[Adjuvant treatment for esophagogastric junction cancer]. Nihon Geka Gakkai zasshi, 2015, Volume: 116, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Asia; Capecitabine; Carboplatin; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Digestive System Surgical Procedures; Docetaxel; Drug Combinations; Esophageal Neoplasms; Esophagogastric Junction; Europe; Fluorouracil; Humans; Lymph Node Excision; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Taxoids; Tegafur	2015
The Asian Perspective on the Surgical and Adjuvant Management of Esophagogastric Cancer. Surgical oncology clinics of North America, 2017, Volume: 26, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Digestive System Surgical Procedures; Esophageal Neoplasms; Esophagogastric Junction; Fluorouracil; Humans; Neoadjuvant Therapy; Stomach Neoplasms; Treatment Outcome	2017
The role of capecitabine in the management of tumors of the digestive system. Reviews on recent clinical trials, 2009, Volume: 4, Issue:1 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Cholangiocarcinoma; Colonic Neoplasms; Deoxycytidine; Digestive System Neoplasms; Docetaxel; Esophageal Neoplasms; Fluorouracil; Gallbladder Neoplasms; Humans; Irinotecan; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Rectal Neoplasms; Stomach Neoplasms; Taxoids; Treatment Outcome; Vascular Endothelial Growth Factor A	2009
The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials. Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:5 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Australia; Capecitabine; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multicenter Studies as Topic; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk Assessment; Stomach Neoplasms; Time Factors; Treatment Outcome; United Kingdom; Young Adult	2009
Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Esophageal Neoplasms; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Randomized Controlled Trials as Topic; Stomach Neoplasms; Treatment Outcome; Young Adult	2009
Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction. Health technology assessment (Winchester, England), 2011, Volume: 15 Suppl 1 Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Capecitabine; Cisplatin; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Fluorouracil; Humans; In Situ Hybridization, Fluorescence; Meta-Analysis as Topic; Multicenter Studies as Topic; Neoplasm Metastasis; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab	2011
COX-2 inhibitors as radiation sensitizers for upper GI tract cancers: esophagus, stomach, and pancreas. American journal of clinical oncology, 2003, Volume: 26, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Celecoxib; Combined Modality Therapy; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Deoxycytidine; Esophageal Neoplasms; Fluorouracil; Humans; Isoenzymes; Membrane Proteins; Pancreatic Neoplasms; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Radiation-Sensitizing Agents; Stomach Neoplasms; Sulfonamides	2003
[Combined treatment of esophageal cancer: a review]. Medicina (Kaunas, Lithuania), 2004, Volume: 40 Suppl 1 Topics: Adenocarcinoma; Alcohol Drinking; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Brachytherapy; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Deoxycytidine; Diet; Dihematoporphyrin Ether; Esophageal Neoplasms; Gemcitabine; Humans; Irinotecan; Meta-Analysis as Topic; Palliative Care; Photochemotherapy; Platinum Compounds; Postoperative Care; Prospective Studies; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Risk Factors; Smoking; Taxoids; Time Factors	2004
Recent updates in the clinical use of platinum compounds for the treatment of gastrointestinal cancers. Seminars in oncology, 2004, Volume: 31, Issue:6 Suppl 14 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Esophageal Neoplasms; Gastrointestinal Neoplasms; Gemcitabine; Humans; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Platinum Compounds; Stomach Neoplasms	2004
Docetaxel in the treatment of esophageal cancer. Seminars in oncology, 2005, Volume: 32, Issue:2 Suppl 4 Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Fluorouracil; Gemcitabine; Humans; Ifosfamide; Irinotecan; Neoadjuvant Therapy; Taxoids	2005
Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers. Cancer, 2006, Jul-15, Volume: 107, Issue:2 Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Esophageal Diseases; Esophageal Neoplasms; Fluorouracil; Humans; Stomach Neoplasms	2006
Capecitabine: in advanced gastric or oesophagogastric cancer. Drugs, 2007, Volume: 67, Issue:4 Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Esophageal Neoplasms; Fluorouracil; Humans; Prodrugs; Stomach Neoplasms; Treatment Outcome	2007
[Gemcitabine and digestive carcinomas]. Bulletin du cancer, 2007, Volume: 94 Spec No Actualites Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Cisplatin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Digestive System Neoplasms; Esophageal Neoplasms; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Organoplatinum Compounds; Pancreatic Neoplasms; Pyridines; Stomach Neoplasms	2007
Medical treatment for advanced gastroesophageal adenocarcinoma. Current opinion in gastroenterology, 2007, Volume: 23, Issue:6 Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Combinations; Epirubicin; Esophageal Neoplasms; Fluorouracil; Humans; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome	2007

Trials

72 trial(s) available for deoxycytidine and Cancer of Esophagus

Article	Year
Efficacy of Bevacizumab and Gemcitabine in Combination with Cisplatin in the Treatment of Esophageal Cancer and the Effect on the Incidence of Adverse Reactions. BioMed research international, 2022, Volume: 2022 Topics: Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Gemcitabine; Humans; Incidence; Keratin-19; Lung Neoplasms; Vascular Endothelial Growth Factor A	2022
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus	2016
A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas. The oncologist, 2013, Volume: 18, Issue:3 Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Esophageal Neoplasms; Esophagogastric Junction; Fluorouracil; Humans; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Survival Analysis	2013
Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy. Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:8 Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Remission Induction; Stomach Neoplasms; Survival; Survival Rate; Taxoids; Vitamin B Complex	2013
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. The Lancet. Oncology, 2013, Volume: 14, Issue:6 Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Chi-Square Distribution; Deoxycytidine; Disease-Free Survival; Early Termination of Clinical Trials; Epirubicin; ErbB Receptors; Esophageal Neoplasms; Female; Fluorouracil; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Molecular Targeted Therapy; Multivariate Analysis; Odds Ratio; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Proportional Hazards Models; Protein Kinase Inhibitors; Stomach Neoplasms; Time Factors; Treatment Outcome; United Kingdom	2013
Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. The Lancet. Oncology, 2013, Volume: 14, Issue:7 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate	2013
[Trastuzumab in combination with chemotherapy versus chemotherapy alone for first-line treatment of HER2-positive advanced gastric or gastroesophageal junction cancer: a Phase III, multi-center, randomized controlled trial, Chinese subreport]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2013, Volume: 35, Issue:4 Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; China; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Receptor, ErbB-2; Remission Induction; Retrospective Studies; Stomach Neoplasms; Survival Rate; Trastuzumab; Vomiting	2013
Docetaxel, oxaliplatin and capecitabine (TEX regimen) in patients with metastatic gastric or gastro-esophageal cancer: results of a multicenter phase I/II study. Acta oncologica (Stockholm, Sweden), 2014, Volume: 53, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Taxoids; Treatment Outcome	2014
Phase II trial of second-line chemotherapy with docetaxel and capecitabine in advanced esophageal squamous cell carcinoma. Medical oncology (Northwood, London, England), 2013, Volume: 30, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorouracil; Humans; Male; Middle Aged; Taxoids	2013
Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2014, Volume: 17, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Taxoids; Treatment Outcome	2014
Adding preoperative radiotherapy plus cetuximab to perioperative chemotherapy for resectable esophageal adenocarcinoma: a single-center prospective phase II trial. The oncologist, 2014, Volume: 19, Issue:1 Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Chemoradiotherapy; Cisplatin; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Perioperative Care; Preoperative Care; Prospective Studies; Survivors	2014
Population pharmacokinetics and exposure-response analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer. Cancer chemotherapy and pharmacology, 2014, Volume: 73, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Receptor, ErbB-2; Stomach Neoplasms; Survival Analysis; Trastuzumab; Young Adult	2014
Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study). Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2015, Volume: 18, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bevacizumab; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Stomach Neoplasms; Treatment Outcome	2015
Feasibility RCT of definitive chemoradiotherapy or chemotherapy and surgery for oesophageal squamous cell cancer. British journal of cancer, 2014, Jul-15, Volume: 111, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Feasibility Studies; Female; Fluorouracil; Humans; Male; Neoadjuvant Therapy; Pilot Projects; Treatment Outcome	2014
Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. European journal of cancer (Oxford, England : 1990), 2015, Volume: 51, Issue:5 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Gene Amplification; Gene Dosage; Germany; Humans; Kaplan-Meier Estimate; Lapatinib; Male; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Stomach Neoplasms; Time Factors; Treatment Outcome	2015
Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma. World journal of gastroenterology, 2015, Apr-14, Volume: 21, Issue:14 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prospective Studies; Republic of Korea; Taxoids; Time Factors; Treatment Outcome	2015
Concurrent Neoadjuvant Chemoradiotherapy for Siewert II and III Adenocarcinoma at Gastroesophageal Junction. The American journal of the medical sciences, 2015, Volume: 349, Issue:6 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxaloacetates; Stomach Neoplasms; Survival Rate	2015
A randomised phase II trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastroesophageal cancer (321GO). British journal of cancer, 2017, Feb-14, Volume: 116, Issue:4 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Epirubicin; Esophageal Neoplasms; Feasibility Studies; Female; Fluorouracil; Frail Elderly; Humans; Male; Organoplatinum Compounds; Oxaliplatin; Palliative Care	2017
Nimotuzumab Combined with Chemotherapy is a Promising Treatment for Locally Advanced and Metastatic Esophageal Cancer. Medical science monitor : international medical journal of experimental and clinical research, 2017, Jan-24, Volume: 23 Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Esophageal Neoplasms; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Remission Induction; Retrospective Studies	2017
Multicenter phase II study of capecitabine plus oxaliplatin as a first-line therapy in Chinese patients with advanced gastric cancer. Anti-cancer drugs, 2008, Volume: 19, Issue:8 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; China; Deoxycytidine; Dose-Response Relationship, Drug; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Survival Analysis; Treatment Outcome	2008
Capecitabine, oxaliplatin and radiotherapy: a phase IB neoadjuvant study for esophageal cancer with gene expression analysis. Cancer investigation, 2009, Volume: 27, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboxylesterase; Combined Modality Therapy; Cytidine Deaminase; Deoxycytidine; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Thymidine Phosphorylase	2009
Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer. British journal of cancer, 2008, Sep-16, Volume: 99, Issue:6 Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Therapy, Combination; Epirubicin; ErbB Receptors; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Stomach Neoplasms; Survival Rate; Tissue Distribution; Treatment Outcome	2008
Definitive chemoradiotherapy with capecitabine and cisplatin in patients with esophageal cancer: a pilot study. Journal of Korean medical science, 2009, Volume: 24, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Severity of Illness Index; Survival Rate; Treatment Outcome	2009
Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Aug-10, Volume: 27, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Anticoagulants; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Catheterization, Central Venous; Cisplatin; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Odds Ratio; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Stomach Neoplasms; Thromboembolism; United Kingdom; Warfarin	2009
A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma. British journal of cancer, 2009, Jun-02, Volume: 100, Issue:11 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Progression; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Stomach Neoplasms; Survival Rate	2009
Phase I study of concurrent selective lymph node late course accelerated hyper-fractionated radiotherapy and Capecitabine, Cisplatin for locally advanced esophageal squamous cell carcinoma. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2009, Volume: 93, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Dose Fractionation, Radiation; Esophageal Neoplasms; Female; Fluorouracil; Humans; Lymphatic Irradiation; Lymphatic Metastasis; Male; Middle Aged; Radiation Injuries; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Survival Rate	2009
[Efficacy of Shenyi Capsule combined with gemcitabine plus cisplatin in treatment of advanced esophageal cancer: a randomized controlled trial]. Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine, 2009, Volume: 7, Issue:11 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capsules; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Female; Gemcitabine; Ginsenosides; Humans; Male; Middle Aged; Panax; Phytotherapy; Quality of Life; Survival Rate; Vascular Endothelial Growth Factor A	2009
Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. British journal of cancer, 2010, Feb-02, Volume: 102, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Quality of Life; Stomach Neoplasms; Taxoids	2010
Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, May-01, Volume: 28, Issue:13 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Adjuvant; Taxoids; Time Factors; Treatment Outcome; United States	2010
A phase II study of weekly docetaxel in combination with capecitabine in advanced gastric and gastroesophageal adenocarcinomas. Oncology, 2010, Volume: 78, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Outpatients; Patient Selection; Stomach Neoplasms; Survival Analysis; Taxoids; Young Adult	2010
Phase I study of docetaxel, oxaliplatin and capecitabine (TEX) as first line therapy to patients with advanced gastro-oesophageal cancer. Acta oncologica (Stockholm, Sweden), 2010, Volume: 49, Issue:8 Topics: Adenocarcinoma; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Taxoids; Treatment Outcome	2010
Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study. Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:11 Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Peritoneal Neoplasms; Prognosis; Stomach Neoplasms; Survival Rate	2010
Feasibility study of docetaxel, oxaliplatin and capecitabine combination regimen in advanced gastric or gastroesophageal adenocarcinoma. Hematology/oncology and stem cell therapy, 2010, Volume: 3, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Survival Rate; Taxoids	2010
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Sep-01, Volume: 28, Issue:25 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Stomach Neoplasms	2010
A phase I study of docetaxel, oxaliplatin, & capecitabine (DOC) as first-line therapy of patients with locally advanced or metastatic adenocarcinoma of stomach and GE junction. Cancer investigation, 2010, Volume: 28, Issue:8 Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Esophageal Neoplasms; Fatigue; Fluorouracil; Humans; Male; Middle Aged; Nausea; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Taxoids; Vomiting	2010
Neoadjuvant concurrent chemoradiotherapy with capecitabine and oxaliplatin in patients with locally advanced esophegeal cancer. Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Esophageal Neoplasms; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Young Adult	2012
Phase II study of weekly paclitaxel and capecitabine in patients with metastatic or recurrent esophageal squamous cell carcinoma. BMC cancer, 2011, Sep-02, Volume: 11 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Esophageal Neoplasms; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel	2011
Phase II study of use of a single cycle of induction chemotherapy and concurrent chemoradiotherapy containing capecitabine/cisplatin followed by surgery for patients with resectable esophageal squamous cell carcinoma: long-term follow-up data. Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Esophageal Neoplasms; Esophagectomy; Feasibility Studies; Female; Fluorouracil; Follow-Up Studies; Humans; Induction Chemotherapy; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Time Factors	2012
Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2012, Volume: 15, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asian People; Capecitabine; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Prognosis; Proportional Hazards Models; Receptor, ErbB-2; Stomach Neoplasms; Survival Rate; Trastuzumab	2012
[Efficacy of late accelerated hyperfractionated conformal radiotherapy combined with capecitabine for esophageal carcinoma]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2011, Volume: 33, Issue:9 Topics: Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Squamous Cell; Chemoradiotherapy; Deoxycytidine; Dose Fractionation, Radiation; Esophageal Neoplasms; Esophagitis; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Radiation Pneumonitis; Radiotherapy, Conformal; Remission Induction; Survival Rate	2011
Long-term outcomes of gemcitabine and cisplatin in patients with recurrent or metastatic esophageal squamous cell carcinoma: a phase II trial. Chinese medical journal, 2011, Volume: 124, Issue:23 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Esophageal Neoplasms; Female; Gemcitabine; Humans; Male; Middle Aged	2011
Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO){dagger}. Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:11 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Prospective Studies; Stomach Neoplasms; Taxoids; Treatment Outcome	2012
Toward semi-automated assessment of target volume delineation in radiotherapy trials: the SCOPE 1 pretrial test case. International journal of radiation oncology, biology, physics, 2012, Nov-15, Volume: 84, Issue:4 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Chemoradiotherapy; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Fluorouracil; Humans; Observer Variation; Quality Assurance, Health Care; Radiography; Tumor Burden	2012
Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report. Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:3 Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Myocardial Infarction; Stomach Neoplasms; Stroke Volume; Thromboembolism; Treatment Outcome	2013
Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:3 Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cardiovascular Diseases; Cisplatin; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Recombinant Fusion Proteins; Stomach Neoplasms; Treatment Outcome; Young Adult	2013
Phase I study of imatinib, cisplatin and 5-fluoruracil or capecitabine in advanced esophageal and gastric adenocarcinoma. BMC cancer, 2012, Dec-10, Volume: 12 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Capecitabine; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Female; Fluorouracil; Humans; Imatinib Mesylate; Male; Maximum Tolerated Dose; Middle Aged; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Stomach Neoplasms	2012
A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:9 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Confidence Intervals; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Palliative Care; Probability; Severity of Illness Index; Stomach Neoplasms; Survival Analysis; Treatment Outcome; United Kingdom	2002
Phase I study of gemcitabine in combination with cisplatin, 5-fluorouracil and folinic acid in patients with advanced esophageal cancer. Anti-cancer drugs, 2002, Volume: 13, Issue:8 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged	2002
Gemcitabine and cisplatin for patients with metastatic or recurrent esophageal carcinoma: a Southwest Oncology Group Study. Investigational new drugs, 2004, Volume: 22, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Rate	2004
Phase II study of cisplatin preceding gemcitabine in patients with advanced oesophageal cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Drug Administration Schedule; Esophageal Neoplasms; Female; Gemcitabine; Humans; Infusions, Intravenous; Leukopenia; Male; Middle Aged; Neutropenia; Survival Analysis; Treatment Outcome	2004
Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. British journal of cancer, 2005, Jun-06, Volume: 92, Issue:11 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Treatment Outcome	2005
Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial. British journal of cancer, 2005, Jun-20, Volume: 92, Issue:12 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Feasibility Studies; Female; Fluorouracil; Humans; Male; Middle Aged; Survival Analysis; Taxoids; Treatment Outcome	2005
Phase I study of docetaxel, capecitabine, and carboplatin in metastatic esophagogastric cancer. American journal of clinical oncology, 2005, Volume: 28, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Carboplatin; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neutropenia; Stomach Neoplasms; Taxoids	2005
A phase II trial of gemcitabine, 5-fluorouracil and leucovorin in advanced esophageal carcinoma. Oncology, 2005, Volume: 69, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Deoxycytidine; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis; Treatment Outcome	2005
Phase II study of gemcitabine and cisplatin in locally advanced/metastatic oesophageal cancer. British journal of cancer, 2005, Nov-14, Volume: 93, Issue:10 Topics: Adult; Aged; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Esophageal Neoplasms; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Survival Rate	2005
Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: a phase II study from the North Central Cancer Treatment Group. Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cardia; Deoxycytidine; Dose-Response Relationship, Drug; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome	2006
Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group. Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Stomach Neoplasms; Taxoids	2006
Phase II trial of gemcitabine plus irinotecan in patients with esophageal cancer: a Southwest Oncology Group (SWOG) trial. American journal of clinical oncology, 2006, Volume: 29, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Esophageal Neoplasms; Female; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Survival Analysis; Treatment Outcome	2006
A phase I and II study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma. British journal of cancer, 2006, May-08, Volume: 94, Issue:9 Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Stomach Neoplasms; Survival Analysis; Treatment Outcome	2006
A phase II study of sequential neoadjuvant gemcitabine and paclitaxel, radiation therapy with cisplatin and 5-fluorouracil and surgery in locally advanced esophageal carcinoma. American journal of clinical oncology, 2006, Volume: 29, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Survival Analysis; Treatment Outcome	2006
A Phase I study of capecitabine, carboplatin, and paclitaxel with external beam radiation therapy for esophageal carcinoma. International journal of radiation oncology, biology, physics, 2007, Mar-15, Volume: 67, Issue:4 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Radiotherapy Dosage	2007
First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study. British journal of cancer, 2007, May-07, Volume: 96, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Quality of Life; Stomach Neoplasms; Survival Analysis	2007
A phase I study of docetaxel, oxaliplatin, and capecitabine in patients with metastatic gastroesophageal cancer. American journal of clinical oncology, 2007, Volume: 30, Issue:4 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Taxoids; Treatment Outcome	2007
A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma. Cancer chemotherapy and pharmacology, 2008, Volume: 62, Issue:1 Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Deoxycytidine; Disease Progression; Esophageal Neoplasms; Female; Fluorouracil; Humans; Immunohistochemistry; Male; Middle Aged; Neoplasm Metastasis; Palliative Care; Survival Analysis; Thymidine Phosphorylase; Thymidylate Synthase	2008
Docetaxel, capecitabine and carboplatin in metastatic esophagogastric cancer: a phase II study. Cancer investigation, 2007, Volume: 25, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboplatin; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Stomach Neoplasms; Survival Analysis; Taxoids	2007
Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer. Medical oncology (Northwood, London, England), 2007, Volume: 24, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Female; Gemcitabine; Humans; Male; Middle Aged; Taxoids; Treatment Outcome	2007
Capecitabine and oxaliplatin for advanced esophagogastric cancer. The New England journal of medicine, 2008, Jan-03, Volume: 358, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Quality of Life; Stomach Neoplasms; Survival Rate	2008
Phase I trial of nanoparticle albumin-bound paclitaxel in combination with gemcitabine in patients with thoracic malignancies. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2008, Volume: 3, Issue:5 Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Deoxycytidine; Esophageal Neoplasms; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nanoparticles; Paclitaxel; Survival Rate; Treatment Outcome	2008
[Phase I study on DMDC]. Gan to kagaku ryoho. Cancer & chemotherapy, 1996, Volume: 23, Issue:13 Topics: Aged; Antineoplastic Agents; Colonic Neoplasms; Deoxycytidine; Drug Administration Schedule; Esophageal Neoplasms; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Stomach Neoplasms	1996
Gemcitabine-cisplatin: a schedule finding study. Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10, Issue:12 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cross-Over Studies; Deoxycytidine; Drug Administration Schedule; Esophageal Neoplasms; Female; Gemcitabine; Humans; Leukopenia; Linear Models; Lung Neoplasms; Male; Middle Aged; Ovarian Neoplasms; Thrombocytopenia	1999
Phase I study of paclitaxel and day 1/day 8 gemcitabine in patients with solid malignancies. American journal of clinical oncology, 2000, Volume: 23, Issue:4 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Deoxycytidine; Diarrhea; Esophageal Neoplasms; Exanthema; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Neoplasms, Unknown Primary; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Paresthesia; Urinary Bladder Neoplasms; Vomiting	2000
Phase II trial of gemcitabine in patients with previously untreated metastatic cancer of the esophagus or gastroesophageal junction. Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:9 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Deoxycytidine; Esophageal Neoplasms; Esophagogastric Junction; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis	2000

Other Studies

62 other study(ies) available for deoxycytidine and Cancer of Esophagus

Article	Year
The prognostic impact of circulating miRNAs in patients with advanced esophagogastric cancer during palliative chemotherapy. Cancer treatment and research communications, 2021, Volume: 27 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Esophageal Neoplasms; Esophagogastric Junction; Female; Folic Acid; Gemcitabine; Humans; Male; MicroRNAs; Middle Aged; Palliative Care; Prognosis; Progression-Free Survival; Randomized Controlled Trials as Topic; Stomach Neoplasms; Survival Rate	2021
Metformin-induced alterations in nucleotide metabolism cause 5-fluorouracil resistance but gemcitabine susceptibility in oesophageal squamous cell carcinoma. Journal of cellular biochemistry, 2018, Volume: 119, Issue:1 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Drug Synergism; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Metformin; Mice; Thymidine Kinase; Thymidylate Synthase; Thymine Nucleotides; Up-Regulation; Xenograft Model Antitumor Assays	2018
Differentially expressed proteins in the human esophageal cancer cell line Eca‑109, in the presence and absence of gemcitabine. Molecular medicine reports, 2018, Volume: 17, Issue:1 Topics: Antimetabolites, Antineoplastic; Apoptosis; bcl-2-Associated X Protein; CARD Signaling Adaptor Proteins; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Esophageal Neoplasms; Gemcitabine; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein	2018
Gastrointestinal Cancers: Management of Rectal, Hepatocellular, Pancreatic, and Esophageal Cancers. International journal of radiation oncology, biology, physics, 2019, 05-01, Volume: 104, Issue:1 Topics: Carcinoma, Hepatocellular; Deoxycytidine; Esophageal Neoplasms; Gastrointestinal Neoplasms; Gemcitabine; Humans; Liver Neoplasms; Neoadjuvant Therapy; Pancreatic Neoplasms; Prospective Studies	2019
Venous thromboembolism in patients receiving perioperative chemotherapy for esophagogastric cancer. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2014, Volume: 27, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Catheterization, Peripheral; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Fluorouracil; Humans; Length of Stay; Male; Middle Aged; Neoadjuvant Therapy; Perioperative Period; Pulmonary Embolism; Retrospective Studies; Stomach Neoplasms; Survival Rate; Venous Thromboembolism; Venous Thrombosis; Young Adult	2014
The relevance of the Siewert classification in the era of multimodal therapy for adenocarcinoma of the gastro-oesophageal junction. Journal of surgical oncology, 2014, Volume: 109, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anastomotic Leak; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Databases, Factual; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Fluorouracil; Gastrectomy; Hospitals, University; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Predictive Value of Tests; Prognosis; Prospective Studies; Stomach Neoplasms; United Kingdom	2014
Complete pathological response in a patient with metastatic esophageal cancer treated with a regimen of capecitabine, oxaliplatin and docetaxel: a case report. Journal of gastrointestinal cancer, 2014, Volume: 45 Suppl 1 Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Taxoids	2014
Definitive chemoradiotherapy with capecitabine and cisplatin for elder patients with locally advanced squamous cell esophageal cancer. Journal of cancer research and clinical oncology, 2014, Volume: 140, Issue:5 Topics: Aged; Aged, 80 and over; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Retrospective Studies	2014
O-MAX chemotherapy: high activity in metastatic esophagogastric adenocarcinoma and possible relation to subclinical hemolysis. Oncology, 2014, Volume: 87, Issue:6 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Haptoglobins; Hematologic Diseases; Hemolytic-Uremic Syndrome; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Remission Induction; Stomach Neoplasms; Treatment Outcome	2014
A nationwide retrospective study of perioperative chemotherapy for gastroesophageal adenocarcinoma: tolerability, outcome, and prognostic factors. Annals of surgical oncology, 2015, Volume: 22, Issue:5 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Perioperative Care; Prognosis; Retrospective Studies; Stomach Neoplasms; Survival Rate	2015
Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2015, Volume: 41, Issue:3 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Prognosis; Sarcopenia; Stomach Neoplasms; Tomography, X-Ray Computed	2015
A case series of patients with HER2-overexpressed primary metastatic gastroesophageal adenocarcinoma. Anticancer research, 2014, Volume: 34, Issue:12 Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Camptothecin; Capecitabine; Carboplatin; Deoxycytidine; Esophageal Neoplasms; Esophagogastric Junction; Fluorouracil; Humans; Irinotecan; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Receptor, ErbB-2; Retrospective Studies; Stomach Neoplasms; Trastuzumab	2014
Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study. Bulletin du cancer, 2015, Volume: 102, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates; Receptor, ErbB-2; Retrospective Studies; Stomach Neoplasms; Trastuzumab	2015
Tumor regression and survival after perioperative MAGIC-style chemotherapy in carcinoma of the stomach and gastroesophageal junction. BMC surgery, 2015, May-22, Volume: 15 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Drug Administration Schedule; Epirubicin; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; Gastrectomy; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Retrospective Studies; Stomach Neoplasms; Survival Analysis; Treatment Outcome	2015
Gemcitabine Plus Vinorelbine as Second-Line Therapy in Patients With Metastatic Esophageal Cancer Previously Treated With Platinum-Based Chemotherapy. Oncology research, 2016, Volume: 24, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Esophageal Neoplasms; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Platinum; Retreatment; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine	2016
Combined treatment of oxaliplatin and capecitabine in patients with metastatic esophageal squamous cell cancer. World journal of gastroenterology, 2009, Feb-21, Volume: 15, Issue:7 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Disease-Free Survival; Esophageal Neoplasms; Female; Fluorouracil; Humans; Leukopenia; Life Tables; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Patient Selection; Prognosis; Survival Analysis; Time Factors	2009
Initial stage affects survival even after complete pathologic remission is achieved in locally advanced esophageal cancer: analysis of 70 patients with pathologic major response after preoperative chemoradiotherapy. International journal of radiation oncology, biology, physics, 2009, Sep-01, Volume: 75, Issue:1 Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Remission Induction; Survival Analysis	2009
Encephalopathy secondary to capecitabine chemotherapy: a case report and discussion. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2009, Volume: 15, Issue:4 Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Neurotoxicity Syndromes	2009
Alpha-fetoprotein expressing metastastic adenocarcinoma of the esophago-gastric junction responding favorably to capecitabine and oxaliplatin. Anti-cancer drugs, 2009, Volume: 20, Issue:1 Topics: Adenocarcinoma; Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Esophageal Neoplasms; Esophagogastric Junction; Fatal Outcome; Fluorouracil; Humans; Immunohistochemistry; Liver Neoplasms; Magnetic Resonance Imaging; Male; Oxaloacetates; Time Factors; Treatment Outcome	2009
Validation of the Royal Marsden hospital prognostic index in advanced esophagogastric cancer using individual patient data from the REAL 2 study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Jul-01, Volume: 27, Issue:19 Topics: Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Esophagogastric Junction; Fluorouracil; Health Status Indicators; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Multicenter Studies as Topic; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Prognosis; Randomized Controlled Trials as Topic; Stomach Neoplasms	2009
Low-dose hyperradiosensitivity: is there a place for future investigation in clinical settings? International journal of radiation oncology, biology, physics, 2010, Feb-01, Volume: 76, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Progression; Esophageal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Glutamates; Guanine; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; Palliative Care; Pemetrexed; Prospective Studies; Radiation Tolerance; Radiotherapy Dosage; Young Adult	2010
Capecitabine treatment patterns in patients with gastroesophageal cancer in the United States. World journal of gastroenterology, 2009, Sep-21, Volume: 15, Issue:35 Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Esophageal Neoplasms; Female; Fluorouracil; Humans; Insurance, Health, Reimbursement; Male; Middle Aged; Retrospective Studies; Stomach Neoplasms; Treatment Outcome; United States	2009
Tumour regression grade (TRG) analyses in patients with resectable gastro-oesophageal adenocarcinomas treated with platinum-based neoadjuvant chemotherapy. Histopathology, 2009, Volume: 55, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Platinum; Remission Induction; Retrospective Studies; Single-Blind Method; Stomach Neoplasms; Treatment Outcome	2009
[Relationship between the level of RRM1 expression and the sensitivity to gemcitabine in the esophageal squamous cell carcinoma cell lines]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2009, Volume: 31, Issue:9 Topics: Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Esophageal Neoplasms; Gemcitabine; Humans; Ribonucleoside Diphosphate Reductase; RNA Interference; RNA, Messenger; RNA, Small Interfering; Transfection; Tumor Suppressor Proteins	2009
Targeted HER2 treatment in advanced gastric cancer. Oncology, 2010, Volume: 78, Issue:1 Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Fluorouracil; Gene Amplification; Genes, erbB-2; Humans; Lapatinib; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Stomach Neoplasms; Survival Analysis; Trastuzumab	2010
Capecitabine and oxaliplatin for advanced esophagogastric cancer. The New England journal of medicine, 2010, Mar-04, Volume: 362, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Fluorouracil; Humans; Kaplan-Meier Estimate; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms	2010
Neoadjuvant treatment of adenocarcinomas of the gastroesophageal junction and stomach - a feasibility trial combining cisplatin and docetaxel with either 5-fluorouracil or capecitabine. International journal of clinical pharmacology and therapeutics, 2010, Volume: 48, Issue:7 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Stomach Neoplasms; Taxoids	2010
Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcin British journal of cancer, 2010, Sep-07, Volume: 103, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Esophageal Neoplasms; Female; Fluorouracil; Humans; Immunohistochemistry; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis; Thymidine Phosphorylase; Thymidylate Synthase; Treatment Outcome	2010
New recommendation of doses in an ongoing phase II study of docetaxel, oxaliplatin and capecitabine as first line therapy in advanced gastro-oesophageal cancer. Acta oncologica (Stockholm, Sweden), 2011, Volume: 50, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase II as Topic; Denmark; Deoxycytidine; Diarrhea; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Fever; Fluorouracil; Humans; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Practice Guidelines as Topic; Stomach Neoplasms; Survival Analysis; Taxoids; Treatment Outcome	2011
Outcomes of patients with esophageal cancer staged with [¹⁸F]fluorodeoxyglucose positron emission tomography (FDG-PET): can postchemoradiotherapy FDG-PET predict the utility of resection? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Nov-01, Volume: 28, Issue:31 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Contrast Media; Deoxycytidine; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Medical Records; Middle Aged; Multivariate Analysis; Neoplasm Staging; Paclitaxel; Platinum Compounds; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy, Adjuvant; Remission Induction; Retrospective Studies; Treatment Outcome	2010
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy. International journal of radiation oncology, biology, physics, 2011, Nov-01, Volume: 81, Issue:3 Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Deoxycytidine; Dose Fractionation, Radiation; Esophageal Neoplasms; Female; Fluorouracil; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Preoperative Care; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Weight Loss	2011
Outcomes from chemoradiotherapy for patients with esophageal cancer. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2011, Volume: 24, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Survival Rate; Treatment Outcome	2011
Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): the Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial. BMC cancer, 2011, Jun-24, Volume: 11 Topics: Adenocarcinoma; Antineoplastic Agents; Capecitabine; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Epirubicin; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Fluorouracil; Germany; Humans; Multicenter Studies as Topic; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Salvage Therapy; Taxoids; Treatment Outcome	2011
Risk of thromboembolic events after perioperative chemotherapy versus surgery alone for esophageal adenocarcinoma. Annals of surgical oncology, 2012, Volume: 19, Issue:2 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Perioperative Care; Prognosis; Prospective Studies; Risk Factors; Thromboembolism	2012
Nonsurgical management of esophageal adenocarcinoma. Clinical colorectal cancer, 2011, Volume: 10, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Cohort Studies; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Induction Chemotherapy; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Survival Rate; Treatment Outcome	2011
Venous thromboembolism in oesophago-gastric carcinoma: incidence of symptomatic and asymptomatic events following chemotherapy and surgery. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2011, Volume: 37, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Deoxycytidine; Enoxaparin; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Gastrectomy; Humans; Incidence; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Risk Factors; Stomach Neoplasms; Venous Thromboembolism	2011
Acute myeloid leukemia secondary to oxaliplatin treatment for esophageal cancer. Clinical colorectal cancer, 2012, Volume: 11, Issue:2 Topics: Abnormal Karyotype; Adenocarcinoma; Antineoplastic Agents; Capecitabine; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Deoxycytidine; Esophageal Neoplasms; Esophagectomy; Fluorouracil; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Radiotherapy; Translocation, Genetic	2012
Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT. Acta oncologica (Stockholm, Sweden), 2012, Volume: 51, Issue:5 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Epirubicin; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Fluorodeoxyglucose F18; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Multimodal Imaging; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals; Survival Rate; Taxoids; Tomography, X-Ray Computed	2012
Low morbidity after palliation of obstructing gastro-oesophageal adenocarcinoma to restore swallowing function. Danish medical journal, 2012, Volume: 59, Issue:6 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Argon Plasma Coagulation; Capecitabine; Carboplatin; Chemoradiotherapy; Combined Modality Therapy; Deglutition Disorders; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Esophageal Perforation; Esophagogastric Junction; Female; Fluorouracil; Gastrointestinal Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Palliative Care; Prosthesis Failure; Retrospective Studies; Stents; Taxoids	2012
Effects of neo-adjuvant chemotherapy for oesophago-gastric cancer on neuro-muscular gastric function. Molecular biology reports, 2012, Volume: 39, Issue:12 Topics: Acetylcholinesterase; Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carbachol; Chemotherapy, Adjuvant; Cholinergic Agonists; Cisplatin; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Ganglia, Autonomic; Gastric Emptying; Gastric Mucosa; Humans; In Vitro Techniques; Male; Middle Aged; Muscle Contraction; Muscle, Smooth; Neoadjuvant Therapy; Stomach; Stomach Neoplasms	2012
Retrospective study of gemcitabine based chemotherapy for unresectable or recurrent esophagus squamous cell carcinoma refractory to first line chemotherapy. Asian Pacific journal of cancer prevention : APJCP, 2012, Volume: 13, Issue:8 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Esophageal Neoplasms; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Young Adult	2012
Trimodality therapy for stage II-III carcinoma of the esophagus: a dose-ranging study of concurrent capecitabine, docetaxel, and thoracic radiotherapy. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2013, Volume: 8, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Endosonography; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Radiotherapy Dosage; Remission Induction; Survival Rate; Taxoids; Thoracic Neoplasms; Tomography, X-Ray Computed	2013
Early changes in [18F]FLT uptake after chemotherapy: an experimental study. European journal of nuclear medicine and molecular imaging, 2002, Volume: 29, Issue:11 Topics: Antineoplastic Agents; Artifacts; Carcinoma, Squamous Cell; Cell Survival; Cisplatin; Deoxycytidine; Dideoxynucleosides; Dose-Response Relationship, Drug; Esophageal Neoplasms; Fluorodeoxyglucose F18; Fluorouracil; Gemcitabine; Humans; Methotrexate; Radionuclide Imaging; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Statistics as Topic; Tumor Cells, Cultured	2002
Treatment of a patient with advanced esophageal cancer with a combination of mitomycin C and capecitabine: activation of the thymidine phosphorylase as active principle? Onkologie, 2003, Volume: 26, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Activation; Esophageal Neoplasms; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Mitomycin; Neoplasm Recurrence, Local; Neoplasm Staging; Thymidine Phosphorylase; Treatment Outcome	2003
Response of neoplastic meningitis from solid tumors to oral capecitabine. Journal of neuro-oncology, 2003, Volume: 65, Issue:2 Topics: Administration, Oral; Adult; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma; Carcinoma, Ductal, Breast; Deoxycytidine; Esophageal Neoplasms; Female; Fluorouracil; Humans; Magnetic Resonance Imaging; Male; Meningeal Neoplasms; Meningitis; Middle Aged; Prodrugs	2003
Quantitative real time PCR of deoxycytidine kinase mRNA by Light Cycler PCR in relation to enzyme activity and gemcitabine sensitivity. Cancer letters, 2004, Sep-30, Volume: 213, Issue:2 Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Deoxycytidine Kinase; DNA, Complementary; Esophageal Neoplasms; Gemcitabine; Gene Expression Profiling; Humans; Light; Phosphorylation; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sensitivity and Specificity; Transplantation, Heterologous; Treatment Outcome; Urinary Bladder Neoplasms	2004
Can cisplatin and infused 5-fluorouracil be replaced by oxaliplatin and capecitabine in the treatment of advanced oesophagogastric cancer? The REAL 2 trial. Clinical oncology (Royal College of Radiologists (Great Britain)), 2005, Volume: 17, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Esophagogastric Junction; Fluorouracil; Humans; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Stomach Neoplasms	2005
Synergistic growth suppression induced in esophageal squamous cell carcinoma cells by combined treatment with docetaxel and heavy carbon-ion beam irradiation. Oncology reports, 2006, Volume: 15, Issue:4 Topics: Animals; Antineoplastic Agents; Carbon; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Doxorubicin; Esophageal Neoplasms; Fluorouracil; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Rats; Taxoids; Treatment Outcome; X-Rays; Xenograft Model Antitumor Assays	2006
Capecitabine, epirubicin and cisplatin in the treatment of oesophagogastric adenocarcinoma. The Netherlands journal of medicine, 2006, Volume: 64, Issue:5 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Retrospective Studies; Stomach Neoplasms; Survival Analysis	2006
[Hand-foot syndrome with capecitabine therapy]. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2007, Volume: 58, Issue:6 Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Esophageal Neoplasms; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Male; Middle Aged; Scleroderma, Localized; Syndrome	2007
Capecitabine in advanced gastric or oesophagogastric cancer: a viewpoint by Yoon-Koo Kang. Drugs, 2007, Volume: 67, Issue:4 Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Esophageal Neoplasms; Fluorouracil; Humans; Prodrugs; Randomized Controlled Trials as Topic; Stomach Neoplasms	2007
Capecitabine in advanced gastric or oesophagogastric cancer: a viewpoint by Sai-Hong Ignatius Ou and Randall F. Holcombe. Drugs, 2007, Volume: 67, Issue:4 Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Esophageal Neoplasms; Fluorouracil; Humans; Prodrugs; Stomach Neoplasms; Thymidine Phosphorylase	2007
Radiation recall pneumonitis induced by gemcitabine. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2007, Volume: 183, Issue:4 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Esophageal Neoplasms; Female; Gemcitabine; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Pneumonia; Radionuclide Imaging; Treatment Outcome	2007
Successful treatment with low-dose capecitabine for disseminated esophageal adenocarcinoma. Acta oncologica (Stockholm, Sweden), 2007, Volume: 46, Issue:6 Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Disease Progression; Esophageal Neoplasms; Fluorouracil; Humans; Male; Treatment Outcome	2007
Metastatic esophageal adenocarcinoma presenting in the iris. American journal of ophthalmology, 2007, Volume: 144, Issue:3 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Fluorouracil; Humans; Iris Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin	2007
Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancer. International journal of radiation oncology, biology, physics, 2007, Nov-01, Volume: 69, Issue:3 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Chi-Square Distribution; Cisplatin; Deoxycytidine; Disease-Free Survival; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Radiotherapy, Adjuvant; Retrospective Studies	2007
Capecitabine and cisplatin chemotherapy (XP) alone or sequentially combined chemoradiotherapy containing XP regimen in patients with three different settings of stage IV esophageal cancer. Japanese journal of clinical oncology, 2007, Volume: 37, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Radiotherapy, Adjuvant; Survival Analysis	2007
Oesophagectomy after definitive chemoradiation in patients with locally advanced oesophageal cancer. Clinical oncology (Royal College of Radiologists (Great Britain)), 2008, Volume: 20, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Male; Middle Aged; Retrospective Studies; Salvage Therapy; Time Factors; Treatment Outcome	2008
Monochromosome transfer and microarray analysis identify a critical tumor-suppressive region mapping to chromosome 13q14 and THSD1 in esophageal carcinoma. Molecular cancer research : MCR, 2008, Volume: 6, Issue:4 Topics: Alleles; Cell Line, Transformed; Cell Line, Tumor; Chromosome Mapping; Chromosome Segregation; Chromosomes, Human, Pair 13; Deoxycytidine; DNA Methylation; Epithelial Cells; Esophageal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Genome, Human; Humans; Hydroxamic Acids; In Situ Hybridization, Fluorescence; Microarray Analysis; Microsatellite Repeats; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Thrombospondins; Transfection; Tumor Stem Cell Assay	2008
Capecitabine and oxaliplatin for advanced esophagogastric cancer. The New England journal of medicine, 2008, May-01, Volume: 358, Issue:18 Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Drug Costs; Esophageal Neoplasms; Fluorouracil; Humans; Organoplatinum Compounds; Oxaliplatin	2008
Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study. Anti-cancer drugs, 2001, Volume: 12, Issue:4 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Amifostine; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cyclophosphamide; Deoxycytidine; Doxorubicin; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Gemcitabine; Humans; Hypertension; Hypocalcemia; Hypotension; Infusions, Intravenous; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Paclitaxel; Pancreatic Neoplasms; Platinum; Prednisone; Premedication; Retrospective Studies; Vincristine	2001
A single-institution experience with concurrent capecitabine and radiation therapy in gastrointestinal malignancies. International journal of radiation oncology, biology, physics, 2002, Jul-01, Volume: 53, Issue:3 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Radiotherapy Dosage; Radiotherapy, Conformal; Remission Induction; Retrospective Studies; Survival Analysis	2002